Incysus Therapeutics receives US patent for its technology
Biopharma company Incysus Therapeutics has been issued a patent by the U.S. Patent and Trademark Office for “Drug Resistant Immunotherapy for treatment of a cancer.”
According to the company, the patent covers the treatment of brain cancer with the combination of certain chemotherapies and a T cell genetically modified to confer chemotherapy resistance.
According to the company, Incysus has two Investigational New Drug applications (INDs) approved by the U.S. Food and Drug Administration…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Tyler Patchen Source Type: news
More News: Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Health Management | Immunotherapy | Investigational New Drugs | Neurology | New Drug Applications